Profound Medical Corp.
Profound Medical Corp. develops and commercializes MRI-guided, incision-free therapies for treating diseased tissue, centered on its TULSA-PRO and Sonalleve systems. The company is organized around a holding-company structure with operating subsidiaries and serves hospitals, clinics, and physician-led treatment centers in North America, Europe, and Asia.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaMRI-guided prostate therapy systems used for incision-free ablation procedures.
MRI-guided ablation systems marketed mainly outside North America.
One-time-use devices consumed per patient treated on installed systems.
Genius services, procedure support, warranties, and maintenance services.
Tuotteet
Raportoitu · osuus liikevaihdosta- Recurring Non Capital60,4 %
- Capital Equipment39,6 %
Lähde: 10-K FY2025, yhtiön tuotelinjoittain raportoima liikevaihto (SEC XBRL). Osuudet on laskettu näytetyistä riveistä ja ne summautuvat 100 %:iin.
Asiakkaat
Profound sells to hospitals, clinics, and other end-users that perform MRI-guided procedures, often through a mix of direct sales and distributor channels. The buying decision is driven by clinical adoption, compatibility with installed MRI scanners, reimbursement support, and the ability to offer less invasive treatment options to patients.
Buy TULSA-PRO or Sonalleve systems and recurring consumables to perform MRI-guided procedures.
Influence product adoption, procedure protocols, and ongoing clinical utilization.
Purchase and resell products in markets where Profound lacks direct sales coverage.
Philips, Siemens, and GE-related channels support lead generation and distribution.
Strategia
Profound’s strategy is to expand adoption of TULSA-PRO and Sonalleve by building direct sales capability, supporting clinicians, and increasing utilization of installed systems. It also relies on partnerships with MRI scanner manufacturers and clinical evidence generation to improve reimbursement support and broaden market acceptance.
Installed-base utilization and procedure volume drive recurring device and service revenue.
Coverage by government and private payors supports broader clinical adoption.
MRI ecosystem partners help generate leads and reduce commercialization friction.
Wider MRI compatibility and new applications can enlarge the addressable market.
Maantiede
Q1/2026Profound has generated revenue in the United States, Europe, and Asia, with the United States using a hybrid recurring model and international markets relying more on capital sales plus recurring consumables. Its systems are compatible with select MRI scanners from Philips, Siemens, and GE Healthcare, which makes geographic expansion dependent on regulatory approvals, local distribution, and installed MRI ecosystems.
Osuus liikevaihdosta, jonka yhtiö raportoi maantieteellisesti.
Riskit
Profound depends on physician adoption, reimbursement support, and continued regulatory clearance for its MRI-guided therapies. Its commercialization model also exposes it to supplier concentration, distributor credit risk, and reliance on third-party MRI scanner partners for market access and compatibility.
- Physician and clinician adoption riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
The systems require clinical acceptance and procedural use to generate recurring revenue.
Kohdistuu: TULSA-PRO and Sonalleve commercialization
- Reimbursement and coverage riskVaikutus: KorkeaTodennäköisyys: Kohtalainen
Coverage by government and private payors affects market uptake and procedure economics.
Kohdistuu: Clinical evidence and reimbursement efforts
- Single-source supplier dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Some components are sourced from a single supplier, creating supply and quality risk.
Kohdistuu: TULSA-PRO and Sonalleve components
- MRI compatibility and partner dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
Commercial success depends on compatibility with select MRI scanners and partner promotion.
Kohdistuu - Distributor credit and collection riskVaikutus: KeskitasoTodennäköisyys: Kohtalainen
Open-credit sales and international distributor terms can delay or impair cash collection.
Kohdistuu: International distributor channels
Kirjanpito
Harkinnanvaraiset erätCapital equipment, one-time-use devices, and services may be recognized differently.
Vaikutus: Affects quarterly revenue mix and comparability
Distributor sales on open credit require judgment about collectability.
Vaikutus: Affects receivables and bad debt expense
Capital sales can be lumpy relative to recurring device revenue.
Vaikutus: Affects reported growth and margin patterns
The company references share-based compensation in operating expense growth.
Vaikutus: Affects SG&A and R&D expense levels
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Hyperfine, Inc.
HYPR · Electromedical & Electrotherapeutic Apparatus
Sensus Healthcare, Inc.
SRTS · Surgical & Medical Instruments & Apparatus
Fonar Corp
Electromedical & Electrotherapeutic Apparatus
FONAR Corp designs, manufactures, sells, and services MRI scanners, with a distinctive focus on its Upright® MRI system that can image patients in weight-bearing positions.
Profusa, Inc.
NVACW · Surgical & Medical Instruments & Apparatus
ProPhase Labs, Inc.
PRPH · Pharmaceutical Preparations
iRadimed Corporation
IRMD · Surgical & Medical Instruments & Apparatus
IRADIMED Corp designs and sells MRI-compatible medical devices used inside scanner rooms, centered on infusion pumps, patient vital signs monitoring systems, and related disposables and service.
Päivitetty: 24.9.2026